Skip to Content

mutNPM1 status is a prognostic and an independent predictive marker for improved survival with azacitidine

Patients with mutNPM1 who received azacitidine have an improved survival of more than 2.5 years compared to placebo compared to a survival gain of all patients in the study of 9.9 months. This indicates that mutNPM1 status is both a prognostic and an independent predictive marker for improved survival with azacitidine.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top